Literature DB >> 24241339

Diagnosis of type 1 diabetes within the first five years of life influences quality of life and risk of severe hypoglycemia in adulthood.

M Trento1, M Trevisan, E Coppo, A Raviolo, M M Zanone, F Cavallo, M Porta.   

Abstract

Progressive adaptation to disease is paramount to improve quality of life (QoL) and other psychological dimensions in type 1 diabetes (T1DM). This study aimed at identifying possible correlations between QoL, locus of control (LoC) and clinical variables in patients with T1DM followed up for 16 years. Fifty-nine patients (27 women) with T1DM, part of a cohort of 112 followed since 1996, accepted to participate. Patients were divided into those in whom onset of T1DM had been during the first 5 years of life (n = 16) or later. They were also stratified into worsened, stable and improved, based on whether their HbA1c had increased/decreased by 1 percentage point between baseline and last follow-up visit. QoL was measured by the Diabetes Quality of Life questionnaire (DQOL), translated into Italian and re-validated. The LoC was measured by the Peyrot- and Rubin-specific questionnaire. Patients who developed T1DM before age 5 had a better total DQOL score than those who developed it later in life, mainly due to the satisfaction dimension and a tendency to decreased fatalism in adult age. All subjects whose HbA1c had worsened from baseline had had their diagnosis after age 5 and reported more frequent episodes of hypoglycemia. Onset of diabetes after age 5 and more frequent hypoglycemia was more likely in subjects with worsened HbA1c (ORs 7.6, p < 0.10 and 20.3, p < 0.01, respectively, from a multivariate logistic model with HbA1c, dichotomized in 'worsened' vs all others, as dependent variable). Onset of T1DM during the first 5 years of life may result in better QoL and less fatalism in the long term. Presumably, these patients have no memory of disease onset, which may reduce trauma and facilitate adaptation to managing life with diabetes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24241339     DOI: 10.1007/s00592-013-0530-6

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  4 in total

1.  Fatalism, Diabetes Management Outcomes, and the Role of Religiosity.

Authors:  Vincent Berardi; John Bellettiere; Orit Nativ; Slezak Ladislav; Melbourne F Hovell; Orna Baron-Epel
Journal:  J Relig Health       Date:  2016-04

2.  Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.

Authors:  Ryo Iga; Hiroshi Uchino; Ken Kanazawa; Shuki Usui; Masahiko Miyagi; Naoki Kumashiro; Hiroshi Yoshino; Yasuyo Ando; Takahisa Hirose
Journal:  Diabetes Ther       Date:  2017-05-25       Impact factor: 2.945

3.  Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study.

Authors:  Mizuho Yamabe; Mami Kuroda; Yasuyo Hirosawa; Hiromi Kamino; Haruya Ohno; Masayasu Yoneda
Journal:  J Diabetes Investig       Date:  2018-08-06       Impact factor: 4.232

Review 4.  Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Authors:  Diane K Wherrett; Jane L Chiang; Alan M Delamater; Linda A DiMeglio; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; Daniel J Lovell; Trevor J Orchard; Christopher M Ryan; Desmond A Schatz; David S Wendler; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.